Syndrome de détresse respiratoire de l'adulte : Questions médicales fréquentes
Nom anglais: Respiratory Distress Syndrome
Descriptor UI:D012128
Tree Number:C08.618.840
Termes MeSH sélectionnés :
Network Meta-Analysis
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Syndrome de détresse respiratoire de l'adulte : Questions médicales les plus fréquentes",
"headline": "Syndrome de détresse respiratoire de l'adulte : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Syndrome de détresse respiratoire de l'adulte : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-24",
"dateModified": "2025-03-19",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Syndrome de détresse respiratoire de l'adulte"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Troubles respiratoires",
"url": "https://questionsmedicales.fr/mesh/D012120",
"about": {
"@type": "MedicalCondition",
"name": "Troubles respiratoires",
"code": {
"@type": "MedicalCode",
"code": "D012120",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C08.618"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Syndrome de détresse respiratoire de l'adulte",
"alternateName": "Respiratory Distress Syndrome",
"code": {
"@type": "MedicalCode",
"code": "D012128",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Lorraine B Ware",
"url": "https://questionsmedicales.fr/author/Lorraine%20B%20Ware",
"affiliation": {
"@type": "Organization",
"name": "Departments of Medicine and Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA."
}
},
{
"@type": "Person",
"name": "Tariq Cheema",
"url": "https://questionsmedicales.fr/author/Tariq%20Cheema",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Carolyn S Calfee",
"url": "https://questionsmedicales.fr/author/Carolyn%20S%20Calfee",
"affiliation": {
"@type": "Organization",
"name": "Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Departments of Medicine and Anesthesia, University of California San Francisco, San Francisco, CA, USA."
}
},
{
"@type": "Person",
"name": "Michael A Matthay",
"url": "https://questionsmedicales.fr/author/Michael%20A%20Matthay",
"affiliation": {
"@type": "Organization",
"name": "Departments of Medicine and Anesthesia, University of California San Francisco, San Francisco, CA, USA."
}
},
{
"@type": "Person",
"name": "Nuala J Meyer",
"url": "https://questionsmedicales.fr/author/Nuala%20J%20Meyer",
"affiliation": {
"@type": "Organization",
"name": "Pulmonary, Allergy and Critical Care Division, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. Electronic address: nuala.meyer@pennmedicine.upenn.edu."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Kenward-Roger-type corrections for inference methods of network meta-analysis and meta-regression.",
"datePublished": "2023-07-03",
"url": "https://questionsmedicales.fr/article/37399845",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jrsm.1652"
}
},
{
"@type": "ScholarlyArticle",
"name": "Diagnostic yield and safety of diagnostic techniques for pulmonary lesions: systematic review, meta-analysis and network meta-analysis.",
"datePublished": "2024-09-18",
"url": "https://questionsmedicales.fr/article/39293856",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1183/16000617.0046-2024"
}
},
{
"@type": "ScholarlyArticle",
"name": "Topical anti-inflammatory treatments for eczema: network meta-analysis.",
"datePublished": "2024-08-06",
"url": "https://questionsmedicales.fr/article/39105474",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD015064.pub2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Systemic corticosteroids for the prevention of bronchopulmonary dysplasia, a network meta-analysis.",
"datePublished": "2023-08-31",
"url": "https://questionsmedicales.fr/article/37650547",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD013730.pub2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Percutaneous coronary intervention in calcified stenoses: a protocol for a systematic review with meta-analysis, trial sequential analysis and network meta-analysis.",
"datePublished": "2022-09-02",
"url": "https://questionsmedicales.fr/article/36691161",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bmjopen-2022-063884"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies de l'appareil respiratoire",
"item": "https://questionsmedicales.fr/mesh/D012140"
},
{
"@type": "ListItem",
"position": 3,
"name": "Troubles respiratoires",
"item": "https://questionsmedicales.fr/mesh/D012120"
},
{
"@type": "ListItem",
"position": 4,
"name": "Syndrome de détresse respiratoire de l'adulte",
"item": "https://questionsmedicales.fr/mesh/D012128"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Syndrome de détresse respiratoire de l'adulte - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Syndrome de détresse respiratoire de l'adulte",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-08",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Syndrome de détresse respiratoire de l'adulte",
"description": "Comment diagnostique-t-on le SDRA ?\nQuels examens sont utilisés pour le SDRA ?\nQuels critères sont utilisés pour le SDRA ?\nLe SDRA peut-il être confondu avec d'autres maladies ?\nQuels signes cliniques indiquent le SDRA ?",
"url": "https://questionsmedicales.fr/mesh/D012128?mesh_terms=Network+Meta-Analysis&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Syndrome de détresse respiratoire de l'adulte",
"description": "Quels sont les symptômes du SDRA ?\nLe SDRA provoque-t-il de la toux ?\nComment se manifeste l'hypoxie dans le SDRA ?\nLe SDRA entraîne-t-il des douleurs thoraciques ?\nY a-t-il des signes d'anxiété avec le SDRA ?",
"url": "https://questionsmedicales.fr/mesh/D012128?mesh_terms=Network+Meta-Analysis&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Syndrome de détresse respiratoire de l'adulte",
"description": "Comment prévenir le SDRA ?\nLe sevrage tabagique aide-t-il à prévenir le SDRA ?\nLes vaccinations peuvent-elles prévenir le SDRA ?\nLe contrôle des maladies chroniques aide-t-il ?\nLes soins postopératoires peuvent-ils prévenir le SDRA ?",
"url": "https://questionsmedicales.fr/mesh/D012128?mesh_terms=Network+Meta-Analysis&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Syndrome de détresse respiratoire de l'adulte",
"description": "Quels traitements sont disponibles pour le SDRA ?\nLe SDRA nécessite-t-il une hospitalisation ?\nLes corticostéroïdes sont-ils utilisés pour le SDRA ?\nLa ventilation non invasive est-elle efficace pour le SDRA ?\nLe SDRA peut-il être traité par des médicaments ?",
"url": "https://questionsmedicales.fr/mesh/D012128?mesh_terms=Network+Meta-Analysis&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Syndrome de détresse respiratoire de l'adulte",
"description": "Quelles sont les complications du SDRA ?\nLe SDRA peut-il entraîner des séquelles ?\nLe SDRA augmente-t-il le risque de décès ?\nQuelles infections peuvent survenir avec le SDRA ?\nLe SDRA peut-il causer des problèmes cardiaques ?",
"url": "https://questionsmedicales.fr/mesh/D012128?mesh_terms=Network+Meta-Analysis&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Syndrome de détresse respiratoire de l'adulte",
"description": "Quels sont les facteurs de risque du SDRA ?\nL'âge influence-t-il le risque de SDRA ?\nLe tabagisme est-il un facteur de risque ?\nLes maladies pulmonaires chroniques augmentent-elles le risque ?\nLes interventions chirurgicales augmentent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D012128?mesh_terms=Network+Meta-Analysis&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on le SDRA ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le SDRA est diagnostiqué par des examens cliniques, radiographies et tests de gaz du sang."
}
},
{
"@type": "Question",
"name": "Quels examens sont utilisés pour le SDRA ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les radiographies thoraciques et les tomodensitométries sont couramment utilisées."
}
},
{
"@type": "Question",
"name": "Quels critères sont utilisés pour le SDRA ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères de Berlin classifient le SDRA en léger, modéré et sévère selon l'hypoxie."
}
},
{
"@type": "Question",
"name": "Le SDRA peut-il être confondu avec d'autres maladies ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut être confondu avec des pneumonies ou des embolies pulmonaires."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent le SDRA ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent une respiration rapide, une cyanose et une détresse respiratoire."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes du SDRA ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent une dyspnée, une tachypnée et une hypoxie sévère."
}
},
{
"@type": "Question",
"name": "Le SDRA provoque-t-il de la toux ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une toux sèche peut être présente, mais elle n'est pas toujours significative."
}
},
{
"@type": "Question",
"name": "Comment se manifeste l'hypoxie dans le SDRA ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'hypoxie se manifeste par une saturation en oxygène faible et une cyanose."
}
},
{
"@type": "Question",
"name": "Le SDRA entraîne-t-il des douleurs thoraciques ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs thoraciques peuvent survenir, mais elles ne sont pas toujours présentes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes d'anxiété avec le SDRA ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'anxiété peut être présente en raison de la difficulté à respirer."
}
},
{
"@type": "Question",
"name": "Comment prévenir le SDRA ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par la gestion des facteurs de risque et le traitement précoce des infections."
}
},
{
"@type": "Question",
"name": "Le sevrage tabagique aide-t-il à prévenir le SDRA ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, arrêter de fumer réduit le risque de complications pulmonaires, y compris le SDRA."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles prévenir le SDRA ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations contre la grippe et le pneumocoque peuvent réduire le risque."
}
},
{
"@type": "Question",
"name": "Le contrôle des maladies chroniques aide-t-il ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un bon contrôle des maladies chroniques comme l'asthme peut aider à prévenir le SDRA."
}
},
{
"@type": "Question",
"name": "Les soins postopératoires peuvent-ils prévenir le SDRA ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des soins postopératoires appropriés peuvent réduire le risque de SDRA après une chirurgie."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour le SDRA ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut l'oxygénothérapie, la ventilation mécanique et le traitement de la cause sous-jacente."
}
},
{
"@type": "Question",
"name": "Le SDRA nécessite-t-il une hospitalisation ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la plupart des cas de SDRA nécessitent une hospitalisation en soins intensifs."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes sont-ils utilisés pour le SDRA ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les corticostéroïdes peuvent réduire l'inflammation dans certains cas de SDRA."
}
},
{
"@type": "Question",
"name": "La ventilation non invasive est-elle efficace pour le SDRA ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut être efficace dans les cas légers, mais la ventilation invasive est souvent nécessaire."
}
},
{
"@type": "Question",
"name": "Le SDRA peut-il être traité par des médicaments ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments peuvent être utilisés pour traiter la cause sous-jacente, mais pas le SDRA directement."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications du SDRA ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'insuffisance respiratoire, les infections et les lésions pulmonaires."
}
},
{
"@type": "Question",
"name": "Le SDRA peut-il entraîner des séquelles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des séquelles pulmonaires peuvent persister après la guérison du SDRA."
}
},
{
"@type": "Question",
"name": "Le SDRA augmente-t-il le risque de décès ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le SDRA a un taux de mortalité élevé, surtout dans les cas sévères."
}
},
{
"@type": "Question",
"name": "Quelles infections peuvent survenir avec le SDRA ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les infections pulmonaires, comme la pneumonie, sont fréquentes chez les patients atteints de SDRA."
}
},
{
"@type": "Question",
"name": "Le SDRA peut-il causer des problèmes cardiaques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le SDRA peut entraîner des complications cardiaques en raison de l'hypoxie prolongée."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque du SDRA ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent les infections, les traumatismes, la pneumonie et les maladies chroniques."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de SDRA ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées ont un risque accru de développer un SDRA."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme augmente le risque de complications pulmonaires et de SDRA."
}
},
{
"@type": "Question",
"name": "Les maladies pulmonaires chroniques augmentent-elles le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maladies comme la BPCO augmentent le risque de développer un SDRA."
}
},
{
"@type": "Question",
"name": "Les interventions chirurgicales augmentent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines interventions chirurgicales, surtout thoraciques, peuvent augmenter le risque de SDRA."
}
}
]
}
]
}
Network meta-analysis has been an essential methodology of systematic reviews for comparative effectiveness research. The restricted maximum likelihood (REML) method is one of the current standard inf...
With recent advancements in bronchoscopic procedures, data on the best modality to sample peripheral pulmonary lesions (PPLs) is lacking, especially comparing bronchoscopy with computed tomography-gui...
We performed a meta-analysis, pairwise meta-analysis and network meta-analysis on studies reporting diagnostic yield and complications with the use of CT-TBNA, radial endobronchial ultrasound (rEBUS),...
We included 363 studies. The overall pooled diagnostic yield was 78.1%, the highest with CT-TBNA (88.9%), followed by RAB (84.8%) and the least with rEBUS (72%). In the pairwise meta-analysis, only rE...
Although CT-TBNA is the most effective approach to sample PPLs, RAB has a comparable diagnostic yield with a lesser complication rate. Further prospective studies are needed comparing CT-TBNA and RAB....
Eczema (atopic dermatitis) is the most burdensome skin condition worldwide and cannot currently be prevented or cured. Topical anti-inflammatory treatments are used to control eczema symptoms, but the...
To compare and rank the efficacy and safety of topical anti-inflammatory treatments for people with eczema using a network meta-analysis....
We searched the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase and trial registries on 29 June 2023, and checked the reference lists of included studies....
We included within-participant or between-participant randomised controlled trials (RCTs) in people of any age with eczema of any severity, but excluded trials in clinically infected eczema, seborrhoe...
We used standard Cochrane methods. Primary outcomes were patient-reported eczema symptoms, clinician-reported eczema signs and investigator global assessment. Secondary outcomes were health-related qu...
We included 291 studies involving 45,846 participants with the full spectrum of eczema severity, mainly conducted in high-income countries in secondary care settings. Most studies included adults, wit...
Potent TCS, JAK inhibitors and tacrolimus 0.1% were consistently ranked as amongst the most effective topical anti-inflammatory treatments for eczema and PDE-4 inhibitors as amongst the least effectiv...
Despite considerable improvement in outcomes for preterm infants, rates of bronchopulmonary dysplasia (BPD) remain high, affecting an estimated 33% of very low birthweight infants, with corresponding ...
To determine whether differences in efficacy and safety exist between high-dose dexamethasone, moderate-dose dexamethasone, low-dose dexamethasone, hydrocortisone, and placebo in the prevention of BPD...
We searched the Cochrane Library for all systematic reviews of systemic corticosteroids for the prevention of BPD and searched for completed and ongoing studies in the following databases in January 2...
We included randomized controlled trials (RCTs) in preterm infants (< 37 weeks' gestation) at risk for BPD that evaluated systemic corticosteroids (high-dose [≥ 4 mg/kg cumulative dose] dexamethasone,...
Our main information sources were the systematic reviews, with reference to the original manuscript only for data not included in these reviews. Teams of two paired review authors independently perfor...
We included 59 studies, involving 6441 infants, in our analyses. Only six of the included studies provided direct comparisons between any of the treatment (dexamethasone or hydrocortisone) groups, for...
Low-dose dexamethasone increased the risk for cerebral palsy (RR 1.92, 95% CI 1.12 to 3.28; moderate-certainty evidence) compared with control. Hydrocortisone may decrease the risk of major neurosenso...
No effect was observed for the outcomes of major neurosensory disability or cerebral palsy. The evidence for the primary outcomes was of overall low certainty, with notable deductions for imprecision ...
While early treatment with moderate-dose dexamethasone or late treatment with high-dose dexamethasone may lead to the best effects for survival without BPD, the certainty of the evidence is low. There...
Severely calcified coronary stenoses are difficult to treat with percutaneous coronary interventions. The presence of severe calcifications complicates lesion preparation, advancement of stents and ac...
We will conduct a systematic review of randomised trials enrolling patients with calcified coronary artery disease undergoing percutaneous coronary intervention. We will investigate any percutaneous t...
No ethics approval is required for this study. The results will be published in a peer-reviewed journal in this field....
CRD42021226034....
Multiple sclerosis (MS) is a chronic disease of the central nervous system that affects mainly young adults (two to three times more frequently in women than in men) and causes significant disability ...
To compare adverse effects of immunotherapies for people with MS or clinically isolated syndrome (CIS), and to rank these treatments according to their relative risks of adverse effects through networ...
We searched CENTRAL, PubMed, Embase, two other databases and trials registers up to March 2022, together with reference checking and citation searching to identify additional studies....
We included participants 18 years of age or older with a diagnosis of MS or CIS, according to any accepted diagnostic criteria, who were included in randomized controlled trials (RCTs) that examined o...
We used standard Cochrane methods for data extraction and pairwise meta-analyses. For NMAs, we used the netmeta suite of commands in R to fit random-effects NMAs assuming a common between-study varian...
This NMA included 123 trials with 57,682 participants...
We found mostly low and very low-certainty evidence that drugs used to treat MS may not increase SAEs, but may increase withdrawals compared with placebo. The results suggest that there is no importan...
A comprehensive network meta-analysis comparing the effects of individual sodium-glucose cotransporter 2 (SGLT2) inhibitors on patients with and without comorbidities including diabetes mellitus (DM),...
We searched PubMed, Embase, Cochrane, and ClinicalTrials.gov for randomized controlled trials up to March 28, 2023. Network meta-analysis using a random-effects model was conducted to calculate risk r...
A total of fourteen trials with 75,334 patients were analyzed. Among these, 40,956 had taken SGLT2 inhibitors and 34,378 had not. One of the main results with particular findings was empagliflozin use...
Our network meta-analysis revealed that empagliflozin users with diabetes experienced a lower risk of dying from any cause than those using dapagliflozin. Additionally, canagliflozin users demonstrate...
PROSPERO [CRD42022361906]....
Multiple randomized controlled trials, each comparing a subset of competing interventions, can be synthesized by means of a network meta-analysis to estimate relative treatment effects between all int...
Surgical treatment of complete rectal prolapse can be undertaken via an abdominal or a perineal approach. The present network meta-analysis aimed to compare the outcomes of different abdominal and per...
A PRISMA-compliant systematic review of PubMed, Scopus, and Web of Science was conducted. Randomized clinical trials comparing two or more procedures for the treatment of complete rectal prolapse were...
Nine randomized controlled trials with 728 patients were included. The follow-up ranged between 12 and 47 months. Posterior mesh rectopexy had significantly lower odds of recurrence than did the Altem...
Posterior mesh rectopexy ranked best with the lowest recurrence while perineal procedures ranked worst with the highest recurrence rates....
Several vaccines showed a good safety profile and significant efficacy against COVID-19. Moreover, in the absence of direct head to head comparison between COVID-19 vaccines, a network meta-analysis t...
Databases PubMed, CENTRAL, medRxiv, and clinicaltrials.gov were searched. Studies were included if they were placebo-controlled clinical trials and reported the safety profile and/or effectiveness of ...
Forty-nine clinical trials that included 421,173 participants and assessed 28 vaccines were included in this network meta-analysis. The network meta-analysis showed that Pfizer is the most effective i...
We found that almost all of the vaccines included in this study crossed the threshold of 50% efficacy. However, some of them did not reach the previously mentioned threshold against the B.1.351 varian...